⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3626662 | 0.67 | — | — | |
| SCHEMBL29858 | 0.65 | — | — | |
| SCHEMBL453887 | 0.65 | — | — | |
| SCHEMBL240497 | 0.65 | — | — | |
| SCHEMBL1884419 | 0.65 | CYP1A2 (0.38) | — | |
| SCHEMBL12820 | 0.64 | — | — | |
| SCHEMBL971778 | 0.63 | RAB9A (0.35) | — | |
| Hydrochloric Acid SCHEMBL28163755 | 0.62 | ALDH1A1 (0.46) | — | |
| SCHEMBL2003061 | 0.62 | — | — | |
| SCHEMBL16782197 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634953-B1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-4151627-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20220251098-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2022-08-11 | — | — | US | disclosed |
| EP-3781156-A1 | SPIROCYCLIC COMPOUNDS | C4 Therapeutics, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20200165256-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
| WO-2019204354-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| US-9877958-B2 | Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160206611-A1 | APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-07-21 | — | — | US | disclosed |
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-6951857-B2 | Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma | FREYNE EDDY JEAN EDGARD | 2005-10-04 | — | — | US | disclosed |
| US-6743792-B2 | ANTIINFLAMMATORY AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-01 | — | — | US | disclosed |
| US-20030220331-A1 | Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma | FREYNE EDDY JEAN EDGARD (BE) | 2003-11-27 | — | — | US | disclosed |
| EP-0889881-B1 | NEW TRIAZOLES AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | NAEJA PHARMACEUTICAL INC (CA) | 2003-04-23 | — | — | EP | disclosed |
| US-20020042416-A1 | Antiinflammatory agents | FREYNE EDDY JEAN EDGARD (BE) | 2002-04-11 | — | — | US | disclosed |
| US-6153616-A | Triazoles as therapeutic agents for fungal infections | SYNPHAR LABORATORIES, INC. (CA) | 2000-11-28 | — | — | US | disclosed |
| EP-1003729-A1 | 6-AZAURACIL DERIVATIVES AS IL-5 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999002504-A1 | 6-AZAURACIL DERIVATIVES AS IL-5 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
| EP-0889881-A1 | NEW TRIAZOLES AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | SYNPHAR LABORATORIES INC. (CA) | 1999-01-13 | — | — | EP | disclosed |
| WO-1998031675-A1 | NEW TRIAZOLES AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | SYNPHAR LABORATORIES, INC. (US) | 1998-07-23 | — | — | WO | disclosed |